April 25, 2018 1:09 PM ET

Biotechnology

Company Overview of Ascenta Therapeutics, Inc.

Key Executives for Ascenta Therapeutics, Inc.

NameBoard RelationshipsTitleAge
Marc Estes Lippman 27 RelationshipsCo-Founder and Director72
Jeffrey Brill No RelationshipsAssociate Director of Clinical Development--
Carl J. Wheeler Ph.D.No RelationshipsVice President of Intellectual Property--

Ascenta Therapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Marc Estes Lippman 27 RelationshipsAscenta Therapeutics, Inc.72
View All Board Members

Ascenta Therapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
There is no committee data available.
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
389.9K
Bonus
258.3K
Total Short Term Compensation
382.6K
Total Value of Options
4.7M
Compensation as of Fiscal Year
Ascenta Therapeutics, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Lysogene Announces Board Changes
April 23, 2018 6:00 AM ET
Kalvista Pharmaceuticals, Inc. Announces Board Changes
April 20, 2018 8:11 PM ET
Marc E. Goldberg Resigns from the Board of CohBar, Inc
April 20, 2018 8:10 PM ET
Orphan Biovitrum Names Fredrik Wetterlundh as New Head of Human Resources
April 20, 2018 6:19 PM ET
Mariola Soehngen Not to Renew Her Position as Member and Chief Executive Officer on the Board of Directors of Mologen AG Which Expires on 31 October 2018
April 20, 2018 5:14 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ascenta Therapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.